アブストラクト
Japanese
| Title | - 乳癌診療ガイドライン (2018年版) のエッセンスと改訂ポイントの解説 - |
|---|---|
| Subtitle | カレントトピックス |
| Authors | 高橋將人 |
| Authors (kana) | |
| Organization | 国立病院機構北海道がんセンター 乳腺外科 |
| Journal | 北海道外科雑誌 |
| Volume | 65 |
| Number | 1 |
| Page | 41-45 |
| Year/Month | 2020 / 6 |
| Article | 報告 |
| Publisher | 北海道外科学会 |
| Abstract | 「要旨」乳癌診療ガイドラインは, 2, 3年に一度改訂されてきた. 最新刊の2018年度版では, (1)治療編, (2)疫学・診断編の2刊構造となっている. 外科治療と疫学の変更ポイントとして, 乳房温存手術における断端陽性の定義, センチネルリンパ節転移を認める患者に対する腋窩郭清省略, 遺伝性乳癌卵巣癌症候群における対側リスク低減乳房切除術について解説した. 放射線治療の項目では, 腋窩リンパ節転移の個数により乳房切除後放射線治療(PMRT)が必要かどうかを判断することを記載した. 薬物治療においては, 術後内分泌療法至適投与期間, dose-dense化学療法, 術後トラスツズマブ, ペルツズマブ併用療法, サイクリン依存性キナーゼ(CDK)4/6阻害薬について記載した. 乳腺診療を専門としない外科医を対象に, 彼らが診療する乳癌患者の治療選択に役立つ講演をすることが今回の目的であった. |
| Practice | 臨床医学：外科系 |
| Keywords | 乳癌, ガイドライン, 改訂, 益と害のバランス |
English
| Title | The essence and the revised points of the breast cancer treatment guidelines (2018 version) |
|---|---|
| Subtitle | Current Topics |
| Authors | Masato Takahashi |
| Authors (kana) | |
| Organization | Department of Breast Surgery, NHO Hokkaido Cancer Center |
| Journal | The HOKKAIDO JOURNAL OF SURGERY |
| Volume | 65 |
| Number | 1 |
| Page | 41-45 |
| Year/Month | 2020 / 6 |
| Article | Report |
| Publisher | Hokkaido Surgical Society |
| Abstract | [Summary] The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer have been revised every few years. The latest, 2018, edition has two volumes: (1) treatment and (2) epidemiology and diagnosis. The revised points in surgical treatment and epidemiology are discussed, including definitions of positive margins in breast-conserving surgery, omission of axillary dissection in patients with sentinel lymph node metastasis, and contralateral risk-reducing mastectomy (CRRM) in hereditary breast and ovarian cancer (HBOC) syndromes. In the radiotherapy section, it is stated that the number of axillary lymph node metastases should be used to determine whether post-mastectomy radiotherapy (PMRT) is necessary. For drug treatment, the optimal administration periods for postoperative endocrine therapy, dose-dense chemotherapy, postoperative combination treatment with trastuzumab and pertuzumab, and cyclin-dependent kinase (CDK) 4/6 inhibitors for metastatic breast cancer are described. The purpose of this presentation is to help surgeons who do not specialize in breast cancer care to select the appropriate treatments for their breast cancer patients. |
| Practice | Clinical surgery |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) 日本乳癌学会: 乳癌診療ガイドライン(1)治療編(2)疫学・診断編 2018年版, 金原出版, 2018
- 2) 日本乳癌学会: 患者さんのための乳がん診療ガイドライン 2019年版, 金原出版, 2019
- 3) Buchholz TA, Somerfield MR, Griggs JJ, et al: Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol 32: 1502-6, 2014
- 4) Giuliano AE, Hunt KK, Ballman KV, et al: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Jama 305: 569-75, 2011
- 5) Donker M, van Tienhoven G, Straver ME, et al: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15: 1303-10, 2014
残りの8件を表示する
- 6) Li X, You R, Wang X, et al: Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review. Clin Cancer Res 22: 3971-81, 2016
- 7) McGale P, Taylor C, Correa C, et al: Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383: 2127-35, 2014
- 8) Goss PE, Ingle JN, Pritchard KI, et al: Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 375: 209-19, 2016
- 9) Del Mastro L, De Placido S, Bruzzi P, et al: Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial. Lancet 385: 1863-72, 2015
- 10) von Minckwitz G, Procter M, de Azambuja E, et al: Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med 377: 122-131, 2017
- 11) Finn RS, Martin M, Rugo HS, et al: Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 375: 1925-1936, 2016
- 12) Robertson JFR, Bondarenko IM, Trishkina E, et al: Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 388: 2997-3005, 2016
- 13) Sledge GW, Jr., Toi M, Neven P, et al: The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol, 2019
